pneumocysti
jirovecii
fungu
caus
pneumonia
immunocompromis
patient
infect
human
immunodefici
viru
hiv
receiv
transplant
malign
treat
chemotherapi
immunosuppress
sinc
introduct
antiretrovir
therapi
overal
outcom
p
jirovecii
pneumonia
pcp
hivinfect
patient
improv
mortal
associ
pcp
still
high
nonhivinfect
patient
therefor
better
treatment
strategi
pcp
requir
patient
trimethoprimsulfamethoxazol
tmpsmx
clindamycin
plu
primaquin
cp
intraven
pentamidin
dapson
atovaquon
use
pcp
treatment
recent
group
report
use
caspofungin
salvag
regimen
effect
cyst
trophzoit
regimen
tmpsmx
act
inhibit
folic
acid
synthesi
recommend
drug
choic
form
pcp
howev
patient
tmpsmx
experi
treatment
failur
advers
drug
reaction
adr
hepatotox
nephrotox
bone
marrow
suppress
rash
electrolyt
imbal
etc
data
risk
factor
associ
treatment
failur
adr
tmpsmx
use
establish
individu
treatment
strategi
altern
regimen
thu
investig
risk
factor
associ
treatment
failur
adr
tmpsmx
firstlin
treatment
pcp
studi
perform
asan
medic
center
tertiari
care
teach
hospit
seoul
korea
patient
compat
symptom
radiolog
find
confirm
pcp
immunohistochem
stain
use
bronchoalveolar
lavag
bal
specimen
januari
juli
identifi
patient
younger
year
old
patient
transfer
anoth
hospit
within
day
diagnosi
patient
whose
medic
record
avail
exclud
analysi
work
approv
research
ethic
committe
asan
medic
centr
seoul
republ
korea
irb
inform
consent
waiv
institut
review
board
asan
medic
center
sinc
work
retrospect
studi
without
intervent
involv
extra
clinic
specimen
bal
perform
fiberopt
bronchoscop
use
standard
techniqu
microbiolog
investig
perform
bal
includ
gram
stain
acidfast
stain
cultur
convent
bacteria
mycobacteria
fungi
quantit
cultur
bal
specimen
use
assay
convent
bacteria
threshold
valu
colonyform
unitsml
immunohistochem
stain
detect
p
jirovecii
perform
accord
manufactur
instruct
commerci
avail
mous
monoclon
antibodi
react
human
rodent
pneumocysti
cyst
trophozoit
monoclon
mous
antipneumocysti
jiroveci
clone
code
dako
denmark
cytomegaloviru
cmv
cultur
standard
techniqu
virus
cmv
includ
respiratori
syncyti
viru
influenza
viru
parainfluenza
viru
adenoviru
detect
use
direct
immunofluoresc
assay
respiratori
viru
screen
identif
diagnost
hybrid
athen
oh
usa
amount
bal
fluid
contain
cell
centrifug
rpm
min
room
temperatur
differenti
cell
count
use
determin
percentag
neutrophil
lymphocyt
alveolar
macrophag
use
hemocytomet
chamber
medic
laboratori
technologist
count
cell
laboratori
medicin
specialist
verifi
extract
dna
bal
fluid
perform
qiaamp
dna
minikit
qiagen
valencia
ca
usa
accord
manufactur
instruct
bal
fluid
sampl
centrifug
rpm
min
standard
volum
ml
extract
elut
volum
amplisen
p
jirovecii
carinii
frt
pcr
kit
amplisen
bratislava
slovak
republ
use
semiquantit
measur
p
jirovecii
dna
accord
manufactur
instruct
result
report
cycl
threshold
ct
valu
realtim
pcr
ct
valu
defin
cycl
number
fluoresc
gener
reaction
cross
fluoresc
threshold
medic
record
review
retrospect
demograph
age
gender
underli
condit
hiv
infect
solid
organ
transplant
hematolog
malign
hematopoiet
stem
cell
transplant
solid
tumor
interstiti
lung
diseas
connect
tissu
diseas
immunosuppress
usag
within
past
month
cyclosporin
mycophenol
mofetil
tacrolimu
sirolimu
azathioprin
corticosteroid
laboratori
find
differenti
cell
count
hematocrit
platelet
blood
urea
nitrogen
creatinin
total
bilirubin
aspartatealanin
aminotransferas
creactiv
protein
radiolog
find
treatment
treatment
regimen
adr
adjunct
corticosteroid
usag
ganciclovir
usag
outcom
extracorpor
membran
oxygen
hour
admiss
intens
care
unit
hour
use
mechan
ventil
hour
mortal
assess
vasopressor
usag
oxygen
requir
use
categor
initi
pcp
sever
mild
partial
pressur
arteri
oxygen
mmhg
alveolararteri
oxygen
differ
moder
mmhg
sever
mmhg
clinic
decis
treatment
regimen
pcp
made
attend
physician
use
adjunct
corticosteroid
defin
use
begun
within
hour
initi
specif
pcp
therapi
consist
least
mg
prednison
twice
daili
day
regardless
subsequ
taper
schedul
treatment
failur
defin
clinic
deterior
first
day
therapi
lack
improv
day
treatment
adr
defin
appreci
harm
unpleas
reaction
result
intervent
relat
use
drug
predict
hazard
futur
administr
warrant
prevent
specif
treatment
alter
dosag
regimen
withdraw
product
identifi
risk
factor
associ
tmpsmx
treatment
failur
adr
patient
requir
salvag
regimen
owe
treatment
failur
adr
categor
case
group
other
respond
tmpsmx
categor
control
group
statist
calcul
use
spss
version
spss
chicago
il
usa
categor
variabl
compar
use
chisquar
test
fisher
exact
test
continu
variabl
analyz
mannwhitney
u
test
binari
logist
regress
model
multivari
analys
construct
use
stepwis
forward
method
first
univari
analysi
covari
perform
covari
signific
p
use
multivari
analys
convert
continu
variabl
categor
variabl
receiv
oper
characterist
curv
use
test
twotail
differ
consid
signific
p
studi
period
patient
diagnos
pcp
identifi
among
patient
seven
patient
younger
year
old
two
patient
transfer
anoth
hospit
within
day
diagnosi
one
patient
whose
medic
record
restrict
exclud
analysi
therefor
total
patient
includ
analysi
solid
organ
transplant
hematolog
malign
common
underli
condit
patient
underw
solid
organ
transplant
includ
receiv
transplant
kidney
liver
pancrea
simultan
kidney
pancrea
heart
patient
hematolog
malign
includ
diffus
larg
b
cell
lymphoma
acut
myeloid
leukemia
acut
lymphoblast
leukemia
adult
peripher
tcell
lymphoma
tlymphoblast
leukemialymphoma
mantl
cell
lymphoma
b
cell
lymphoma
burkitt
lymphoma
angioimmunoblast
tcell
lymphoma
hodgkin
diseas
pure
red
cell
aplasia
retinoblastoma
unspecifi
lymphoma
patient
hematolog
malign
two
patient
receiv
hematopoiet
stem
cell
transplant
patient
solid
tumor
includ
breast
cancer
nonsmal
cell
lung
cancer
small
cell
lung
cancer
advanc
gastric
cancer
prostat
cancer
pancreat
cancer
other
dermatomyos
glomerolonephr
system
lupu
nephriti
antineutrophil
cytoplasm
antibodyassoci
vascul
interstiti
lung
diseas
ulcer
coliti
nine
patient
infect
hiv
initi
bacteri
respiratori
viru
coinfect
found
five
staphylococcu
aureu
klebsiella
pneumonia
burkholderia
cepacia
moraxella
catarrhali
viridian
group
streptococcu
nine
patient
coronaviru
rhinoviru
influenza
viru
respiratori
syncyti
viru
respect
twentyon
patient
cmv
viremia
patient
cmv
cultur
bal
fluid
patient
cmv
tissueinvas
diseas
median
time
symptom
onset
start
treatment
day
interquartil
rang
iqr
day
median
treatment
durat
day
iqr
day
thirtynin
patient
need
salvag
treatment
owe
either
treatment
failur
adr
tmpsmx
usag
nephrotox
common
adr
follow
bone
marrow
suppress
electrolyt
imbal
gastrointestin
troubl
hepatotox
except
two
patient
receiv
cp
plu
caspofungin
one
receiv
tmpsmx
plu
caspofungin
patient
receiv
cp
secondlin
regimen
patient
need
salvag
treatment
mortal
rate
rate
treatment
failur
cp
secondlin
regimen
patient
receiv
caspofungin
salvag
regimen
surviv
patient
receiv
extracorpor
membran
oxygen
also
surviv
secondari
prophylaxi
done
patient
median
durat
treatment
month
iqr
day
relaps
occur
two
patient
univari
analysi
solid
organ
transplant
underli
condit
tacrolimu
mycophenol
mofetil
immunosuppress
diabet
chronic
kidney
diseas
chronic
heart
failur
comorbid
glomerular
filtrat
rate
gfr
mlmin
laboratori
find
consolid
radiograph
find
frequent
found
case
group
tabl
bal
fluid
analysi
white
blood
cell
wbc
count
iqr
vs
iqr
p
lymphocyt
percentag
iqr
vs
iqr
p
absolut
lymphocyt
count
alc
iqr
vs
iqr
p
lower
neutrophil
percentag
iqr
vs
iqr
p
higher
case
group
tabl
multivari
analysi
diabet
mellitu
dm
adjust
odd
radio
aor
condifid
interv
ci
gfr
mlmin
aor
ci
lymphocyt
percentag
aor
ci
independ
associ
treatment
failur
adr
tmpsmx
tabl
sensit
specif
posit
predict
valu
neg
predict
valu
three
risk
factor
tmpsmx
treatment
failur
adr
ci
ci
ci
ci
respect
none
patient
three
risk
factor
die
within
day
replac
bal
lymphocyt
percentag
bal
wbc
bal
alc
bal
wbc
bal
alc
also
statist
signific
independ
risk
factor
associ
treatment
failur
adr
tmpsmx
data
shown
analysi
exclud
two
patient
adr
treatment
failur
underli
condit
aor
confid
interv
diabet
mellitu
aor
confid
interv
bal
lymphocyt
aor
confid
interv
statist
independ
risk
factor
associ
treatment
failur
tmpsmx
usag
thefirst
line
regimen
pcp
treatment
tabl
studi
dm
gfr
mlmin
bal
lymphocyt
percentag
found
risk
factor
associ
treatment
failur
adr
tmpsmx
usag
firstlin
regimen
pcp
treatment
knowledg
studi
first
identifi
risk
factor
associ
tmpsmx
treatment
failur
adr
previou
studi
look
associ
cellular
profil
bal
fluid
prognosi
neutrophil
count
bal
fluid
report
associ
prognosi
retrospect
studi
done
jansen
et
al
hivinfect
patient
die
respiratori
complic
higher
neutrophil
percentag
bal
fluid
compar
patient
surviv
retrospect
studi
nonhivinfect
patient
done
asan
medic
center
mortal
increas
patient
pcp
neutrophil
percentag
bal
fluid
associ
neutrophil
bal
fluid
mortal
attribut
bacteri
coinfect
sever
inflammatori
reaction
induc
neutrophilproduc
cytokin
studi
also
reveal
higher
percentag
neutrophil
bal
fluid
patient
experienc
tmpsmx
treatment
failur
adr
regardless
high
neutrophil
percentag
found
absolut
neutrophil
count
differ
case
control
wbc
count
bal
fluid
lower
patient
without
tmpsmx
treatment
failur
adr
tabl
low
lymphocyt
count
bal
fluid
may
explain
high
neutrophil
percentag
low
wbc
count
bal
fluid
result
suggest
alveolar
lymphocyt
may
play
import
role
alveolar
neutrophil
count
pcp
pathogenesi
well
known
blood
lymphocyt
count
import
pcp
progress
prognosi
howev
studi
associ
bal
lymphocyt
count
pcp
prognosi
studi
hivinfect
patient
respiratori
complic
rate
pcp
bal
fluid
count
independ
risk
factor
moral
author
review
previou
data
collect
asan
medic
center
bal
lymphocyt
percentag
iqr
vs
iqr
p
bal
absolut
lymphocyt
count
iqr
vs
iqr
p
lower
patient
show
tmpsmx
treatment
failur
adr
case
present
studi
proport
bal
lymphocyt
percentag
also
statist
significantli
higher
patient
vs
p
result
suggest
blood
lymphocyt
count
also
alveolar
lymphocyt
count
play
import
role
pcp
treatment
mani
studi
prognosi
pcp
old
age
sever
diseas
assess
oxygen
requir
need
mechan
ventil
underli
condit
hematolog
malign
vascul
low
count
shown
associ
poor
prognosi
howev
knowledg
nonmodifi
prognost
factor
help
establish
treatment
strategi
contrari
knowledg
risk
factor
associ
treatment
failur
adr
tmpsmx
usag
allow
creation
individu
treatment
strategi
pcp
instanc
patient
risk
factor
posit
predict
valu
treatment
failur
adr
tmpsmx
usag
altern
regimen
cp
consid
thefirst
line
regimen
inde
studi
small
number
patient
pcp
show
similar
efficaci
tmpsmx
cp
firstlin
regimen
addit
like
dm
gfr
low
bal
lymphocyt
might
nonspecif
factor
link
underli
diseas
rather
pcp
treatment
confirmatori
conclus
postpon
prospect
studi
larg
number
patient
sever
pcp
show
efficaci
altern
regimen
inferior
tmpsmx
studi
individu
strategi
use
risk
factor
identifi
studi
carri
studi
sever
limit
first
judgement
treatment
failur
tmpsmx
might
consist
clinician
sinc
studi
pcp
perform
asan
medic
center
accumul
evid
reflect
standard
practic
experienc
infecti
diseas
expert
decid
criteria
treatment
failur
describ
method
section
standard
practic
indirectli
verifi
assess
bal
simultan
give
tmpsmx
firstlin
regimen
cp
secondlin
regimen
patient
standard
practic
may
result
better
prognosi
current
studi
compar
previou
studi
second
composit
paramet
treatment
failur
adr
use
evalu
outcom
studi
subgroup
analysi
risk
factor
associ
treatment
failur
dm
bal
lymphocyt
still
signific
third
heterogen
underli
condit
could
affect
outcom
pcp
studi
need
patient
specif
homogen
underli
condit
hiv
solid
organ
transplant
conclus
dm
initi
gfr
mlmin
bal
lymphocyt
percentag
independ
risk
factor
associ
treatment
failur
adr
develop
tmpsmx
usag
firstlin
regimen
pcp
treatment
result
suggest
bal
lymphocyt
count
may
play
role
pcp
treatment
studi
follow
reveal
role
bal
lymphocyt
pcp
treatment
